Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Carcinoma, Renal Cell 144Carcinoma, Non-Small-Cell Lung 51Carcinoma, Transitional Cell 50Melanoma 46Urinary Bladder Neoplasms 42Prostatic Neoplasms 32Kidney Neoplasms 29Neoplasm Metastasis 27Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Hepatocellular 20Triple Negative Breast Neoplasms 15Neoplasms 15Stomach Neoplasms 14Ovarian Neoplasms 14Clear-cell metastatic renal cell carcinoma 14Lung Neoplasms 13Uterine Cervical Neoplasms 12Carcinoma, Merkel Cell 11Small Cell Lung Carcinoma 9Pancreatic Neoplasms 9Head and Neck Neoplasms 8Esophageal Neoplasms 7Breast Neoplasms 7Urethral Neoplasms 6Endometrial Neoplasms 6Cholangiocarcinoma 6Urogenital Neoplasms 5Skin Neoplasms 5Recurrence 5

Interventions

pembrolizumab 3belinostat 2enzalutamide 1apalutamide 1abiraterone 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Nivolumab × Genitourinary × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡